0001567619-22-012509.txt : 20220608 0001567619-22-012509.hdr.sgml : 20220608 20220608134451 ACCESSION NUMBER: 0001567619-22-012509 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 EFFECTIVENESS DATE: 20220608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Centrexion Therapeutics Corp CENTRAL INDEX KEY: 0001592052 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320402377 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-448502 FILM NUMBER: 221003177 BUSINESS ADDRESS: STREET 1: 200 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: (617) 837-6911 MAIL ADDRESS: STREET 1: 200 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Centrexion Corp DATE OF NAME CHANGE: 20131114 D 1 primary_doc.xml X0708 D LIVE 0001592052 Centrexion Therapeutics Corp 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 617-837-6911 DELAWARE None Centrexion Corp Corporation true Jeffrey B. Kindler 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Executive Officer Director James N. Campbell, M.D. 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Executive Officer Director Randall M. Stevens 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Executive Officer Michael J. Ward 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Executive Officer Sol Barer 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director Colin Hill 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director Dezhi Kang, Ph.D. 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director J. C. Lopez, M.D. 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director Joseph R. Swedish 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director Shawn Tomasello 200 STATE STREET, 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 Director Peter Wirth 200 STATE STREET, 6TH FLOOR Boston MA MASSACHUSETTS 02109 Director Biotechnology Decline to Disclose 06b false 2022-05-24 false true true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue 16th Floor New York NY NEW YORK 10022 All States false 16475000 16475000 0 false 25 0 1482750 true The compensation payable to the finder (Maxim Group LLC) consisted of (i) a cash fee (listed above) plus (ii) the issuance of approximately 269,092 shares of common stock and (iii) and a warrant to purchase up to 988,500 shares common stock. 0 false Centrexion Therapeutics Corp /s/ Michael Ward Michael Ward Chief Financial Officer, Treasurer, and Secretary 2022-06-08